New RapiFluor-MS labelling reagent and sample preparation protocol greatly enhances speed, sensitivity, simplicity of released N-Glycan profiling and characterisation
Waters Corporation announced new technology for characterising glycoproteins. The technology introduction at WCBP 2015, includes the new GlycoWorks RapiFluor-MS N-Glycan Kit, the Waters ACQUITY UPLC, the ACQUITY UPLC FLR Detector and the ACQUITY QDa detector, and enables scientists to analyse released N-glycans and achieve new levels of speed, sensitivity, simplicity while obtaining previously unattainable structural information.
New RapiFluor-MS labelling reagent and sample preparation protocol greatly enhances speed, sensitivity, simplicity of released N-Glycan profiling and characterisation.
This new set of technologies enables fast de-glycosylation and labelling, and a workflow that reduces sample preparation time from a day to less than one hour; allows mass detection for characterization and development with sensitivity that is 100 to 1,000-fold better than current approaches; and enables routine laboratory use supported by a simple robust protocol without involving MS experts.
“Today’s introduction is a ground-breaking approach to glycan analyses. It means scientists can monitor and characterise released N-glycans like never before,” said Mike Yelle, Vice President, Consumable Business Unit, Waters Division. “The new workflows take what had been a specialised and complicated activity and transform it into one which scientists and laboratories can be successful with.”
Most biotherapeutic proteins are glycoproteins and the heterogeneous glycan populations on these proteins are critical quality attributes that affect potency, stability, and therapeutic safety profiles. New drug submissions to regulatory agencies must contain detailed structural information pertaining to the attached glycans and proof the glycoprotein can be manufactured with a consistent glycan profile.
EP News Bureau – Mumbai